Suchergebnisse

The need for AI-readiness in federal procurement will continue to grow with the capabilities of AI tools. There are concrete steps the government could take to ensure all development and implementation of AI-related laws, regulations, and executive branch policies include appropriate considerations.

The authors examine how to craft, assess, and implement an organizational design in the U.S. Air Force to design a force that is effective at deterring and fighting a peer adversary and fund and field that force in a time frame that meets warfighting needs.

The authors identify ways to improve the U.S. Space Force's (USSF's) capability requirements development to help USSF achieve its core mission in the face of rapidly developing adversary capabilities in space.

In this first volume of four reports examining nine case studies of budgeting processes across comparative organizations, RAND Corporation researchers conduct case studies of the defense budgeting processes of China and Russia.

This report, part of a four-volume set, presents case studies of planning, programming, budgeting, and execution (PPBE) functions in four federal agencies comparable to the U.S. Department of Defense (DoD) to help improve DoD's PPBE processes.

This report adds two case studies of planning, programming, budgeting, and execution (PPBE) functions to those of other U.S. federal government agencies in Volume 3, offering insights for improving the U.S. Department of Defense's PPBE processes.

In this second volume of four reports examining nine case studies of defense budgeting processes across comparative organizations, RAND researchers conducted case studies of the budgeting processes of Australia, Canada, and the United Kingdom.

Abstract The safety and efficacy of elosulfase alfa were evaluated in a multicenter, open-label, phase 3b study in Australian Morquio A patients, consisting of a 49-week initial phase and an extension phase until elosulfase alfa was government funded. Thirteen patients (1-27 years) were enrolled. No new safety concerns were identified over 138 weeks. Most drug-related adverse events were mild or moderate in severity; none led to study discontinuation. After 49 weeks of treatment, median improvements from baseline were seen in the 6-minute walk test (+41.0 m), 3-minute stair climb test (+14.0 stairs/min), forced vital capacity (+16.4%), forced expiratory volume in 1 second (+14.1%), urine keratan sulfate (-7.1 µg/mg creatinine), and pain intensity. Growth, cardiac function, sleep, and quality of life results were mixed or stable. These results provide further evidence of the acceptable safety/tolerability profile of elosulfase alfa. The improvements in endurance, pulmonary function, and pain support findings from previous studies.